United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

TRAP 5 Human, Mouse Monoclonal Antibody, Clone: TRAP-01

  • Regulatory status:RUO
  • Type:Monoclonal Antibody
  • Other names:TRACP 5, Tartrate Resistant Acid Phosphatase 5
  • Species:Human
Cat. No. Size Price
1 pc / 2 - 5 pcs / 6+ pcs

RD182025110-01 0.1 mg $300 / $266 / On request
PubMed Product Details
Technical Data


Monoclonal Antibody


Enzyme Immunoassay

Source of Antigen

Sf 9 cells








The antibody is a mouse monoclonal antibody against Human TRAP 5. The human TRAP 5 is isolated from Sf 9 cells (which expressed rTRAP).

Species Reactivity

Human. Not yet tested in other species.

Purification Method

Affinity chromatography on a column with immobilized protein G.

Antibody Content

0.1 mg (determined by BCA method, BSA was used as a standard)


The antibody is lyophilized in 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. 


Add 0.2 ml of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation.


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


The lyophilized antibody remains stable and fully active until the expiry date when stored at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at -80°C. Reconstituted antibody can be stored at 4°C for a limited period of time; it does not show decline in activity after one week at 4°C.

Quality Control Test

SDS PAGE - to determine purity of the antibody BCA - to determine quantity of the antibody


This product is for research use only.


Research topic

Bone and cartilage metabolism


TRAP 5 (serum band 5 tartrate-resistant acid phosphatase, TRACP 5; EC is a glycoprotein of 35–37 kDa. TRAP 5 belongs to the most abundant enzymes in osteoclasts. It is expressed in certain differentiated cells of the mononuclear phagocyte system, particularly osteoclasts and alveolar macrophages, where it takes an active part in bone resorption process. High blood levels of TRAP 5 are usually associated with active bone remodelling. Increased serum levels are observed during normal bone growth among healthy children. Elevated serum TRAP levels have been detected in diseases characterized by increased bone resorption; Paget’s disease of the bone, hemodialysis, primary hyperparathyro­idism, metastatic malignancies involving bone resorption, multiple myeloma and bilaterally ovariectomized women. Post-menopausal women have higher levels of serum than post-menopausal women on estrogen replacement therapy. Therefore specific determination of TRAP 5 activity can be essential for clinical assessment of bone metabolism.

Summary References (9)

References to TRAP 5

  • Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 1982, 34, 285–290.
  • Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem. 1987, 33, 458–462.
  • Nakanishi M, Yoh K, Uchida K, Maruo S, Matsuoka A. Improved method for measuring tartrate-resistant acid phosphatase activity in serum. Clin Chem. 1998, 44, 221–225.
  • Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrateresistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000, 15, 133–1345.
  • Lamp EC, Drexler HG. Biology of tartrate-resistant acid phosphatase. Leuk Lymphoma. 2000, 39, 477–484.
  • Nakanishi M, Yoh K, Miura T, Ohasi T, Rai SK, Uchida K. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem. 2000, 46, 469–473.
  • Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnose type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab. 2002, 87, 2212–2217.
  • Igarashi Y, Lee M, Matsuzaki S. Acid phosphatases as markers of bone metabolism. J Chromatogr B. 2002, 781, 345–358.
  • Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A. Tartrate-resistant acid phosphatase isoform 5b: a novel serum markerfor monitoring bone disease in multiple myeloma. Int J Cancer. 2003, 106, 455–457.
Related Products Docs